Literature DB >> 8642663

Influenza A virus RNA-dependent RNA polymerase: analysis of RNA synthesis in vitro.

J M Galarza1, Q Peng, L Shi, D F Summers.   

Abstract

Influenza A virus RNA-dependent RNA polymerase, purified from virion ribonucleoprotein particles and from which endogenous genomic RNA (vRNA) has been depleted by treatment with micrococcal nuclease, was used to study transcription initiation, elongation, and termination in vitro. Templates that contained either minus- or plus-sense influenza virus nucleoprotein minigenes with conserved 5' and 3' termini and the uridylate tract were constructed. The dinucleotide ApG and alfalfa mosaic virus RNA4 (AlMV4) were used as primers. ApG primed the synthesis of full-length positive-strand or cRNA products and shorter transcripts, depending upon the molar ratio between the nucleoprotein and the vRNA template. Sequence analysis of the ends of these transcripts demonstrated that the 5' termini of both transcripts and the 3' terminus of the full-length product were complementary to the 3' and 5' termini of the vRNA template, respectively, whereas the 3' terminus of the incomplete product corresponded to a sequence located 40 bases downstream from the 5' terminus of the template and was about 20 nucleotides downstream from the uridylate tract, which is the putative signal for polyadenylation. Binding of the cap structure of AlMV4 by the polymerase activated RNA synthesis by ligation-elongation of small genomic RNA fragments which were likely derived from a genome segment protected by the polymerase from micrococcal nuclease digestion. The sequence of these fragments mapped to a region 14 to 28 nucleotides upstream of the 3' terminus of the viral genome. Polymerase subunit involvement in transcription initiation with ApG or AlMV4 was characterized by studying the effect of purified polyclonal antisubunit immunoglobulins of the G class (IgGs) in transcription assays. These results showed that anti-PB2 IgG inhibited transcription initiation in both ApG- and AlMV4-primed reactions, whereas anti-PB1 antibodies also blocked transcription initiated with AlMV4. The differences observed in product size, product sequence, and differential inhibition by antisubunit IgGs are discussed. These observations would support the notion that the influenza virus RNA-dependent RNA polymerase undergoes a conformational change after the binding of the cap structure of host cell heterogeneous nuclear RNA by PB2, which then usually leads to endonucleolytic cleavage of the capped primer 13 nucleotides downstream from the cap.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642663      PMCID: PMC190078     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Sequencing the termini of capped viral RNA by 5'-3' ligation and PCR.

Authors:  C W Mandl; F X Heinz; E Puchhammer-Stöckl; C Kunz
Journal:  Biotechniques       Date:  1991-04       Impact factor: 1.993

2.  Transcription of the influenza virus genome.

Authors:  A J Hay; B Lomniczi; A R Bellamy; J J Skehel
Journal:  Virology       Date:  1977-12       Impact factor: 3.616

3.  Structure of the ribonucleoprotein of influenza virus.

Authors:  R W Compans; J Content; P H Duesberg
Journal:  J Virol       Date:  1972-10       Impact factor: 5.103

4.  Globin mRNAs are primers for the transcription of influenza viral RNA in vitro.

Authors:  M Bouloy; S J Plotch; R M Krug
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

5.  Characterization of influenza virus RNA complete transcripts.

Authors:  A J Hay; J J Skehel; J McCauley
Journal:  Virology       Date:  1982-01-30       Impact factor: 3.616

6.  Polyadenylation sites for influenza virus mRNA.

Authors:  J S Robertson; M Schubert; R A Lazzarini
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

7.  Are the 5' ends of influenza viral mRNAs synthesized in vivo donated by host mRNAs?

Authors:  R M Krug; B A Broni; M Bouloy
Journal:  Cell       Date:  1979-10       Impact factor: 41.582

8.  5' and 3' terminal nucleotide sequences of the RNA genome segments of influenza virus.

Authors:  J S Robertson
Journal:  Nucleic Acids Res       Date:  1979-08-24       Impact factor: 16.971

9.  Influenza virion transcriptase: synthesis in vitro of large, polyadenylic acid-containing complementary RNA.

Authors:  S J Plotch; R M Krug
Journal:  J Virol       Date:  1977-01       Impact factor: 5.103

10.  Cap and internal nucleotides of reovirus mRNA primers are incorporated into influenza viral complementary RNA during transcription in vitro.

Authors:  M Bouloy; M A Morgan; A J Shatkin; R M Krug
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

View more
  5 in total

1.  In vivo analysis of the TSWV cap-snatching mechanism: single base complementarity and primer length requirements.

Authors:  D Duijsings; R Kormelink; R Goldbach
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

2.  Cellular splicing factor RAF-2p48/NPI-5/BAT1/UAP56 interacts with the influenza virus nucleoprotein and enhances viral RNA synthesis.

Authors:  F Momose; C F Basler; R E O'Neill; A Iwamatsu; P Palese; K Nagata
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Characterization of the in vitro activity of the RNA-dependent RNA polymerase associated with the ribonucleoproteins of rice hoja blanca tenuivirus.

Authors:  M Nguyen; B C Ramirez; R Goldbach; A L Haenni
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

4.  pp32 and APRIL are host cell-derived regulators of influenza virus RNA synthesis from cRNA.

Authors:  Kenji Sugiyama; Atsushi Kawaguchi; Mitsuru Okuwaki; Kyosuke Nagata
Journal:  Elife       Date:  2015-10-29       Impact factor: 8.140

5.  Development of a method for evaluating the mRNA transcription activity of influenza virus RNA-dependent RNA polymerase through real-time reverse transcription polymerase chain reaction.

Authors:  Yuka Horio; Mototada Shichiri; Yuji Isegawa
Journal:  Virol J       Date:  2021-08-28       Impact factor: 4.099

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.